Project Grant R01AI183533
Award Date
12/26/24
Completion Date
11/30/29
Dollars Obligated
$813K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, DC 20052, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
This $699,814 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the molecular mechanisms of Plasmodium-Anopheles midgut interactions and evaluate novel targets for malaria transmission-blocking vaccines. The primary objectives are to characterize mosquito and Plasmodium proteins that mediate parasite invasion of the mosquito midgut, determine their...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $832,071 to Seattle Children's Hospital to develop potent transmission-reducing monoclonal antibodies and optimized vaccines targeting the HAP2 and HAP2P antigens of the malaria parasite. The research aims to create a universal transmission-blocking vaccine effective against multiple Plasmodium species and overcome key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $310,492 in funding to the University of Washington to conduct research on understanding and overcoming Plasmodium-specific immune evasion mechanisms. The research aims to characterize the circumsporozoite protein (CSP)-specific memory B cell pool generated during Plasmodium infection versus immunization, and...
This federal Project Grant award of $708,202 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research aims to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The key products and services to be delivered include: Conducting a case-control study in Kenya to identify infants and children with severe malaria...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant to L2 Diagnostics LLC under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate a mosquito salivary protein, AGBR1, as a potential vaccine candidate against Chikungunya virus, an arboviral disease transmitted by infected mosquitoes. The project aims to conduct comparative assessments of different AGBR1 vaccine formulations, including...
This federal Project Grant award of $375,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into the functions of messenger ribonucleoproteins (mRNPs) in regulating mRNA metabolism and translation in the malaria parasite Plasmodium falciparum. The research aims to identify molecular markers for distinct mRNP granules, determine their compositions, and characterize their...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $392,710 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Georgia Research Foundation to establish continuous, high-yield culture systems for the Plasmodium vivax (P. vivax) malaria parasite. This research aims to develop key tools to study P. vivax's asexual and sexual stages, enabling mechanistic research to identify and develop new therapies. The grant also includes a...
This $406,450 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop continuous in vitro culture and genetic methods for the Plasmodium vivax malaria parasite. The primary objectives are to: 1) optimize the production of reticulocytes (young red blood cells) to support P. vivax culture, 2) optimize culture conditions in a bespoke bioreactor using iterative machine...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $700,288.00 in funding to the University of South Florida to conduct research on identifying genetic factors associated with the sexual stage development of the malaria parasite Plasmodium falciparum. The project leverages a functional genomics approach using random PiggyBac mutagenesis to screen for genes...